Can a 100 mg Luvox (fluvoxamine) tablet be split?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Luvox 100 mg Tablets Be Split?

No, Luvox (fluvoxamine) 100 mg tablets should not be split. The FDA-approved dosing for fluvoxamine specifies that doses above 100 mg should be given in two divided doses using intact tablets, not by splitting higher-strength tablets 1.

Rationale Based on FDA Labeling

The official FDA prescribing information for Luvox provides clear guidance on dosing 1:

  • Starting dose: 50 mg once daily at bedtime
  • Titration: Increase in 50 mg increments every 4-7 days as tolerated
  • Doses >100 mg/day: Should be given in two divided doses (not split tablets)
  • Maximum dose: 300 mg/day in adults

The FDA label explicitly states that when total daily doses exceed 100 mg, they "should be given in two divided doses. If the doses are not equal, the larger dose should be given at bedtime" 1. This refers to using multiple intact tablets of appropriate strengths, not splitting a single higher-strength tablet.

Why Splitting Is Problematic for Fluvoxamine

Fluvoxamine has specific characteristics that make tablet splitting inadvisable:

  1. Twice-daily dosing requirement: At doses of 100 mg or higher, fluvoxamine requires twice-daily administration due to its pharmacokinetic profile 2, 1. The 100 mg strength is designed as a single dose, not to be split into two 50 mg doses.

  2. Dose uniformity concerns: Research demonstrates that unscored tablets or tablets not designed for splitting frequently fail weight and content uniformity tests 3. Fluvoxamine tablets are not specifically manufactured with splitting in mind.

  3. Discontinuation syndrome risk: Fluvoxamine is associated with discontinuation syndrome 4, making precise dosing critical. Inaccurate doses from split tablets could inadvertently lead to subtherapeutic levels and withdrawal symptoms.

Evidence on Tablet Splitting Generally

While some medications can be safely split, the practice requires careful consideration 5:

  • Approximately 15-16% of split tablets fall outside acceptable weight and content uniformity specifications 3
  • Sustained-release formulations should never be split (though standard fluvoxamine is not sustained-release) 5
  • Unscored tablets are particularly problematic for splitting 6

Common pitfalls with tablet splitting:

  • Fragment or powder loss during splitting leads to dose variability 3
  • Elderly patients may struggle physically to split tablets accurately 7
  • Lack of clear information in package inserts about divisibility 6

Practical Recommendations

If dose adjustment is needed:

  • Use the commercially available tablet strengths (25 mg, 50 mg, 100 mg) in appropriate combinations
  • For doses between 100-300 mg/day, prescribe multiple intact tablets divided into two daily doses 1
  • Example: For 150 mg/day, prescribe one 100 mg tablet plus one 50 mg tablet, divided appropriately

For pediatric patients (ages 8-17), the starting dose is 25 mg at bedtime, with increases in 25 mg increments 1. Use the 25 mg strength tablets rather than attempting to split 50 mg tablets.

For elderly or hepatically impaired patients, who have decreased clearance 1, use lower intact tablet strengths and slower titration rather than splitting tablets.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.